<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106895</url>
  </required_header>
  <id_info>
    <org_study_id>FORMA-10</org_study_id>
    <nct_id>NCT04106895</nct_id>
  </id_info>
  <brief_title>Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data</brief_title>
  <official_title>Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the characteristics of patients treated with Fibryga®, the indications and
      conditions of use of Fibryga® and, for patients treated &quot; on-demand&quot;, the short-term
      outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of treatments given for an ongoing bleeding episodes</measure>
    <time_frame>6 months</time_frame>
    <description>Estimate the proportion of treatments given for an ongoing bleeding episodes (opposed to preventative treatment administered for example before surgery or to regular prophylaxis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>On-demand Treatment Success</measure>
    <time_frame>6 months</time_frame>
    <description>on-demand treatment of spontaneous or surgical bleeding episodes, success is defined as bleeding control (complete cessation of bleeding or &lt; 20% decrease in hemoglobin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Prophylaxis Success</measure>
    <time_frame>6 months</time_frame>
    <description>Surgical prophylaxis success is defined as no bleeding or oozing and control of bleeding with fibrinogen concentrate (as anticipated or requiring increased dosing or additional infusions not originally anticipated).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Fibryga</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibryga</intervention_name>
    <description>Fibryga</description>
    <arm_group_label>Fibryga</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients having received Fibryga® (&quot;on-demand&quot; or for regular prophylaxis) in the centres
        participating in the study during the recollection period (limited to 7 patients by centre
        and by period). A total of 4 recollection periods is planned by centre.

        Data from all consecutive patients having received Fibryga® whatever the indication
        (congenital or acquired fibrinogen deficiency; &quot;on-demand&quot; or regular prophylaxis) will be
        collected. The data collection will be limited to 7 patients by centre and by period,
        meaning that only data from the 7 first patients treated during the recollection period
        willbe collected.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with fibrinogen deficiency (congenital or acquired)

          -  Having received an treatment with Fibryga® during the recollection period

          -  Having been informed of the potential retrospective collection of their data by a
             Clinical Research Associate mandated by Octapharma® when Fibryga® has been delivered
             and who did not refuse.

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikaela Raymond</last_name>
    <phone>866-337-1868</phone>
    <email>ctgov@clinicalresearchmgt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bordeaux Study Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33404</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Le Plessis Robinsin Study Site</name>
      <address>
        <city>Le Plessis-Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marseille Study Site</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nantes Study Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valence Study Site</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

